Magic mushrooms have stumbled the news in a big way over the last few years, with a series of most broadcasted studies recommending they may be an effective treatment for depression and other psychological ailments. However, the effects of psychedelic drugs can be irregular, with some people finding the experience overwhelmingly scary. To try and address this problem, a psychedelic research and development corporation is now attempting to create a strain of sacred mushroom that only ever cases good trips.
It is well known that the psychoactive effects of hallucinogenic sprouts are primarily is provided by a molecule announced psilocybin, although many of these fungu contain a range of other complexes that may influence the psychedelic experience by interacting with psilocybin- a phenomenon known as the entourage effect.
Little research has been conducted into these other molecules, although a company announced CaaMTech has invested the past year or so investigating the assets of several psilocybin analogs, and believes it may have identified one that can completely eliminate bad trips. Speaking to Double Blind, CaaMTech founder Andrew Chadeayne explained that a combination called aeruginascin may well be the key to ensuring a positive sprout experience.
“We want to come up with a way to at least give people the option of increasing the probability for a rapturous event versus a dysphoric ordeal, ” he said.
Inspiration for the project came from a newspaper released in 1989, which analyzed the experiences of a number of people who had unwittingly ingested sacred mushroom. Many of these accidental trippers reported feelings of anxiety, panic, and a “deep dysphoric mood”, although everyone else who has depleted a mushroom categories announced Inocybe aeruginascens all described highly positive experiences.
Since < em> I. aeruginascens is the only mushroom known to contain aeruginascin, study writer Jochen Gartz concluded that “aeruginascin seems to modify the pharmacological action of psilocybin to give an ever euphoric humor during ingestion of the mushrooms.”
Due to the small sample size and shortcoming of proper scientific testing, nonetheless, this watching has been widely challenged. Much more study is needed before such exhaustive words about the effects of aeruginascin can be made. For one thing, the trimethylammonium organization of aeruginascin means that it is unlikely to pass through the blood-brain barrier, drawing it seem unlikely that it could possibly be psychoactive.
However, Chadeayne told Double Blind that his company’s latest research- which remains unpublished- demonstrates that a metabolite of aeruginascin called 4-OH-TMT does in fact pass the blood-brain barrier and bind to the same serotonin receptors that most psychedelic drugs act upon.
“We’re actually the only beings in the world to know that this is active at the serotonin receptors, ” he said, before explaining that the company won’t be advocating the use of aeruginascin until it has conducted meticulous research into its safety and efficacy.
And just in case you were thinking of going out and searching for some < em> I. aeruginascens , em> bear in mind that aeruginascin is similar in design to a toad venom called bufotenidine, which has been pondered to begin temporary paralysis when ingested in high-pitched amounts.
Be cool and wait for the research.
[ H/ T: Double Blind]